DaVita lowers purchase price of medical group by $560 million
DaVita still hasn't sold its medical group. Photo: RJ Sangosti/The Denver Post via Getty Images
Why it matters: DaVita, a dominant provider of dialysis treatment, lowered the price due in large part to deteriorating financials within the physician business. The Federal Trade Commission has still not signed off on this deal, and DaVita wants to close the deal to offset growing debt, as it prepares for federal changes to commercial insurance for dialysis.